Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (KURA) granted inducement stock options for 48,450 shares to four new employees on September 1, 2026, under its 2023 Inducement Option Plan. The awards were approved by the Board’s Compensation Committee as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $12.89 per share, equal to the closing price on the grant date, and vests over four years: 25% after one year, with the remaining shares vesting monthly over the following 36 months, subject to continued service. The options are governed by the 2023 Inducement Option Plan and individual option agreements. Kura develops precision oncology medicines, including FDA-approved KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated acute myeloid leukemia.
Kura Oncology (Nasdaq: KURA) announced that management will present at three healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference on September 8 at 3:45 p.m. ET, Cantor Global Healthcare Conference on September 9 at 9:10 a.m. ET, and Morgan Stanley Global Healthcare Conference on September 16 at 7:45 a.m. ET. Live audio webcasts and replays will be available in the Investors section of Kura’s website.
Kura Oncology (Nasdaq: KURA) reported second quarter 2026 results highlighted by the commercial ramp of KOMZIFTI (ziftomenib) and progress across its precision oncology pipeline. KOMZIFTI generated $9.1 million in net product revenue, up 57% quarter over quarter, with approximately 115 new patient starts (+35%) and more than 250 total prescriptions (+59%), achieving a majority share of new patient starts in the R/R NPM1-mutant AML menin inhibitor class.
Total revenue was $20.9 million, including $11.8 million in collaboration revenue, and Kura reported a net loss of $68.3 million. The company ended the quarter with $519.0 million in cash, cash equivalents and short-term investments and expects, together with $180 million in anticipated Kyowa Kirin collaboration payments, to fund ziftomenib AML development through topline Phase 3 KOMET-017 data expected in 2028. Multiple ziftomenib and darlifarnib clinical readouts are planned over the next 12–18 months.
Kura Oncology (Nasdaq: KURA) reported publication in Blood of a manuscript detailing the discovery and preclinical characterization of ziftomenib (KOMZIFTI), a once-daily oral menin inhibitor approved in 2025 for adult patients with relapsed or refractory NPM1‑mutated AML without satisfactory alternatives.
The paper describes ziftomenib’s differentiated menin binding profile, potent and selective inhibition of the menin‑KMT2A interaction, robust on‑target activity across KMT2A‑rearranged, NPM1‑mutated and NUP98‑rearranged leukemia models, and its ability to induce leukemia regression and extend survival in xenograft and patient‑derived xenograft models.
Researchers also show that ziftomenib retains activity against certain treatment‑emergent MEN1 resistance mutations where other menin inhibitors did not; in the KOMET‑001 trial, MEN1‑M327I emerged in 1 of 29 evaluable patients. Kura continues to develop ziftomenib in combinations across molecularly defined AML populations and other oncology indications, while highlighting boxed warnings and safety information from the U.S. prescribing label.
Kura Oncology (Nasdaq: KURA) announced that on August 3, 2026, its Board Compensation Committee granted inducement awards of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees under the 2023 Inducement Option Plan, as amended.
The options have an exercise price of $9.19 per share, equal to the August 3, 2026 closing price, and vest over four years: 25% after one year and the remaining shares monthly over the following 36 months, subject to continued service. The awards were approved as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update.
The live webcast and archived replay will be available on Kura’s website under the Investors > Events and Presentations section. Kura is a biopharmaceutical company focused on precision medicines for cancer, including KOMZIFTI (ziftomenib), an FDA-approved, once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
Kura Oncology (Nasdaq: KURA) reported updated Phase 1a data from the FIT-001 trial of darlifarnib plus cabozantinib in cabozantinib-naïve, pretreated patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC). Among 34 evaluable patients, objective response rates ranged from 33% to 50% across darlifarnib dose levels, with a median progression-free survival of 13 months across pooled doses and median duration of response not yet estimable at most levels due to ongoing responses.
The combination showed durable clinical benefit, with more than half of patients on treatment at data cutoff, and a manageable safety profile in 72 RCC patients, generally consistent with the individual drugs. According to Kura Oncology, these results support further development of darlifarnib plus cabozantinib, and a global, randomized Phase 1b portion comparing the combination versus cabozantinib alone is underway to define a recommended Phase 3 dose ahead of a planned registrational study in 2028.
Kura Oncology (Nasdaq: KURA) will present updated long-term follow-up data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced clear cell renal cell carcinoma at the 2026 Kidney Cancer Research Summit in Boston on July 24, 2026.
The company is also enrolling a global randomized Phase 1b trial comparing the combination versus cabozantinib alone to inform a planned registrational Phase 3 study in 2028 and will host a virtual investor call on July 27, 2026.
Kura Oncology (Nasdaq: KURA) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4) to five new employees. On July 1, 2026, the compensation committee granted nonstatutory stock options for 68,750 shares at a per-share exercise price of $10.78, vesting over four years.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported long-term Phase 1/2 KOMET-007 data for ziftomenib + 7+3 in newly diagnosed NPM1-m and KMT2A-r AML.
12‑month OS was 94% for NPM1-m and 71% for KMT2A-r; CRc reached 96% and 90%, with high MRD negativity and a generally manageable safety profile supporting the ongoing Phase 3 KOMET-017 program.